Hypercoagulation after neoadjuvant immunochemotherapy as a new prognostic indicator in patients with locally advanced gastric cancer undergoing surgery

Table 1 Patients’ characteristics

Parameters	Number
Age [median (range)]	58 (31-75)
Gender, male/female (n)	81/23
BMI (kg/m2) (mean ± SD)	22.82 ± 2.81
Smoking status, never smoker/ever smoker (n)	76/28
Drinking status, never drinker/ever drinker (n)	87/17
Plasma D-dimer (mg/L) [median (range)]
Before neoadjuvant treatment	0.32 (0.10-2.43)
Before surgery	0.45 (0.22-3.96)
Plasma fibrinogen (g/L) [median (range)]
Before neoadjuvant treatment	3.30 (1.83-5.66)
Before surgery	2.74 (1.78-6.21)
Tumor location (n)
Upper stomach	55
Middle stomach	14
Lower stomach	35
Clinical T stage (n)
cT3	60
cT4	44
Clinical N stage (n)
cN1	66
cN2	30
cN3	8
Pathological type (n)
Non- signet ring cell carcinoma	81
Signet ring cell carcinoma	23
Chemotherapy regimen, sox/xelox (n)	101/3
Immunotherapy regimen (n)
Sintilimab	13
Toripalimab	8
Nivolumab	6
Tislelizumab	77
Median follow-up (months)	21

BMI: Body mass index.